Budapest, June 14, 2019

**Dickkopf-related protein 3 (DKK3) predicts AKI**

Acute kidney injury (AKI) is a common complication after cardiac surgery. The severity fluctuates from subclinical AKI, an increase in biochemical markers of kidney injury, to severe AKI requiring renal replacement therapy with dialysis. Furthermore, AKI impacts hospitalization and mortality. AKI is often diagnosed late – therefore the search for reliable biomarkers for its prediction is important. A new study published in “The Lancet” showed that urinary DKK3 is an indicator of renal tubular cell stress that significantly improves prediction of AKI.

A new renal biomarker was presented at the ERA-EDTA Congress last year: that shows that urinary DKK3 might help to identify patients who are at risk of progressive chronic kidney disease (CKD).

The pathological change that correlates with progressive kidney damage is tubulointerstitial fibrosis, the mechanisms of which are the subject of intensive research at present. Damaged cells of renal tubules produce various cytokines, which on one hand control regenerative processes, but which on the other can also lead to the development of tubulointerstitial fibrosis. Regenerative processes may occur in the early stages of activation, via the well-known Wnt signaling pathway (signaling pathway for cell differentiation and proliferation/regeneration), but continuous Wnt activation is detrimental and induces tubulointerstitial fibrosis. Modulators of the signaling chain include Dickkopf-related (DKK) proteins, which interact with the canonical Wnt signaling pathway. Urinary DKK3 can thus be used as a biomarker for tubular cell stress and progressing tubulointerstitial fibrosis – and therefore potentially as a marker for distinguishing progressive kidney injury.

Yesterday, an observational cohort study was published, which aimed to test the association between the ratio of preoperative urinary concentrations of DKK3 to creatinine (DKK3:creatinine) and postoperative acute kidney injury (AKI), defined according to the Kidney Disease Improving Global Outcomes [KDIGO] criteria, and subsequent kidney function loss.

AKI is a common complication after cardiac surgery. The incidence of cardiac surgery-associated AKI varies widely from 7 to 40% depending upon the patient population, the
procedure and how AKI is defined. The risk increases in patients with known co-
morbidities and the severity fluctuates from subclinical AKI, an increase of biochemical
markers of kidney injury without a decrease in renal function, to severe AKI requiring
renal replacement therapy with dialysis. The development of AKI after cardiac surgery has
a dramatic impact on intensive care unit and hospital length of stay, as well as short- and
long-term mortality. Reliable biomarkers are therefore needed to guarantee an early
diagnosis and intervention.

In the present study nearly 1,000 patients from two cohorts were analyzed. The patients
of one cohort had undergone elective cardiac surgery at the Saarland University Medical
Centre (Homburg, Germany; derivation cohort, n=733). Patients who were undergoing
elective cardiac surgery (selected on the basis of a Cleveland Clinical Foundation score of
6 or higher), and were enrolled in the prospective RenalRIP multicenter trial formed the
second cohort (validation cohort, n=216). In this trial, the patients had been randomized
to remote ischemic preconditioning or a sham procedure.

The analysis of the derivation cohort showed that urinary concentrations of
DDK3:creatinine significantly improved AKI prediction (p<0.0001). High urinary
DDK3:creatinine concentrations were independently associated with significantly lower
kidney function at hospital discharge and after a median follow-up of 820 days.

In the RenalRIP trial, preoperative urinary DDK3:creatinine concentrations higher than
471 pg/mg were associated with a significantly higher risk for AKI (OR: 1.94; p=0.026),
persistent renal dysfunction (p=0.0072), and dialysis dependency (p=0.020) after 90 days
compared with DDK3:creatinine concentrations of 471 pg/mg or less. In patients who
underwent the sham procedure, the AKI risk was even higher (OR: 2.79). According to
the study authors, this indicated that patients with ongoing tubular cell stress might
particularly benefit from remote ischemic preconditioning.

"Urinary DDK3 can significantly improve the prediction of AKI beyond the established
clinical models and available biomarkers. Measurement of urinary DDK3 might therefore
represent a personalized medicine approach in patients having cardiac surgery. It gives us
the chance to detect patients at risk for AKI and subsequent kidney function loss and to
take care of them intensively," explained study investigator Professor Danilo Fliser,
Homburg/Saar (Germany). "A DDK3-ELISA test provides relatively simple identification of
at-risk patients. We think it is time to implement it in clinical practice."
About ERA-EDTA

With more than 7,000 active members, the ERA-EDTA is one of the biggest nephrology associations worldwide leading European nephrology and one of the most important European Medical Associations. It organises annual congresses and a Scientific Education Interactive Day (SEID), it produces guidelines, it collects data and performs epidemiological studies through its Registry. It supports fellowships and research projects. Its publications are NDT and CKJ (this last journal is Open Access). The ERA-EDTA also has an online Educational platform: the European Nephrology Portal (ENP) which includes NDT-Educational@ENP. The 2020 Congress will be held June 6-9 in Milan (Italy). Visit the booth to receive more information!

Web site: www.era-edta.org